Mr. Scott P. Serota, the CEO and president of the BCBSA made the subsequent comments in regards of the selection of Joshua Sharfstein and Margaret Hamburg as the deputy commissioner and the commissioner, accordingly, at the FDA or U.S. Food and Drug Administration.
He said that by nominating Joshua Sharfstein and Margaret to direct the U.S. Food and Drug Administration, the U.S. president Obama has delivered a clear message that he is interested in promoting balance and enhancing supervision at a crucially significant agency whose work is felt by every American. Both of them are much respected and have been foremost in Maryland and New York dealing for improvement of the people's health and safety across communal range.
He added that the FDA is facing with a broad range of urgent and instant challenges and the country's 39 BCBS companies assure their support and help. With BCBS plans offering coverage to almost 102 million people staying at every zip code in the U.S., they have direct experience of what works here and where developments are required now.
He mentioned that they believe, particularly that restructuring the system for assessing and endorsing healthcare devices would considerably promote the healthcare safety in the country. They strongly believe that a transparent regulatory path for bio-generics requirements to be set up as early as possible and that Office of Generic Drugs is required extra sources for meeting its mandate.
BCBS companies have been at lead of all hard works for promoting generic medicines and they are hopeful about dealing with the FDA to assist extending access to effective and safe generic medicines all though the American healthcare system.